New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature

Keyphrases

• Ketoacidosis 100%
• New-onset Diabetes 100%
• Nivolumab 100%
• Programmed Death-ligand 1 (PD-L1) 66%
• Tumor Cells 66%
• Diabetic Ketoacidosis 66%
• Immune Checkpoint Inhibitors 66%
• Immune-related Adverse Events 66%
• Immune Checkpoint Inhibitor Therapy 66%
• Patient Management 33%
• Solid Tumors 33%
• Tumor Subtype 33%
• Black Males 33%
• Endocrine Disorders 33%
• Popular 33%
• Risk Factors 33%
• Cell-to-cell 33%
• Immune Response 33%
• Cancer Cells 33%
• Effective Management 33%
• T-cell Mediated 33%
• Unique Mechanism 33%
• Immune Cells 33%
• First-line Therapy 33%
• Early Recognition 33%
• Cancer Treatment 33%
• Acute Onset 33%
• Type 1 Diabetes Mellitus (T1DM) 33%
• Life-threatening Complications 33%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 33%
• Rare Complication 33%
• Blood Sugar 33%
• Prolonged Use 33%
• Systemic Therapy 33%
• Dextrose 33%
• Non-insulin-dependent Diabetes Mellitus (NIDDM) 33%
• Insulin Infusion 33%
• Lung Neuroendocrine Tumors 33%

Medicine and Dentistry

• Diabetes 100%
• Immunotherapy 100%
• Immune Checkpoint Inhibitor 100%
• Ketoacidosis 100%
• Nivolumab 100%
• Tumor Cell 50%
• Diabetic Ketoacidosis 50%
• Immune-Related Adverse Events 50%
• Solid Malignant Neoplasm 25%
• Clinician 25%
• Awareness 25%
• Diabetes Mellitus 25%
• Cancer Cell 25%
• T Cell 25%
• Immunity 25%
• Immunocompetent Cell 25%
• Cancer Therapy 25%
• Insulin Dependent Diabetes Mellitus 25%
• Endocrine Disease 25%
• Systemic Therapy 25%
• Glucose 25%
• Neuroendocrine Tumor 25%
• CTLA-4 25%
• Lung 25%
• Programmed Death 1 Ligand 1 25%
• Insulin Infusion 25%